Coherus Gears Up For January Udenyca Launch, Prices Biosimilar At 33% Discount To Neulasta

Buoyed by the market share held by biosimilars of the short-acting neutropenia drug Neupogen, Coherus hopes its Udenyca price, contracts and services will give its biosimilar a significant share of the market for the longer-acting Neulasta.